-
1 Comment
Cassiopea S.p.A is currently in a long term downtrend where the price is trading 4.4% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Finally, its free cash flow fell by 0.6% to $-3M since the same quarter in the previous year.
Based on the above factors, Cassiopea S.p.A gets an overall score of 1/5.
| Industry | |
|---|---|
| Sector | |
| ISIN | None |
| CurrencyCode | EUR |
| Exchange | F |
| Target Price | 64.47 |
|---|---|
| PE Ratio | None |
| Market Cap | 378M |
| Dividend Yield | 0.0% |
| Beta | 1.43 |
Cassiopea S.p.A., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing medical dermatology products worldwide. It offers Winlevi, an antiandrogen, which has completed Phase III clinical trial for the topical treatment of acne; Breezula, a topical antiandrogen that is in Phase II clinical trial to treat androgenic alopecia; CB-06-01, a topical antibiotic, which is in Phase II clinical trial for the treatment of acne, including strains resistant to other antibiotics; and CB-06-02, a novel integrin activator that has completed Phase II clinical trial to treat genital warts. The company was formerly known as Cosmo Dermatos S.r.l. Cassiopea S.p.A. was founded in 2013 and is based in Lainate, Italy. As of December 2, 2021, Cassiopea S.p.A. operates as a subsidiary of Cosmo Pharmaceuticals N.V.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for CSP.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
